Global Alzheimer’s Disease Market Growth Propelled by Expanding Geriatric Population

The latest report by IMARC, titled “Alzheimer’s Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2033,” finds that the global Alzheimer’s disease market size is witnessing steady growth. Alzheimer’s disease is a progressive neurodegenerative disorder that affects the brain, leading to a gradual decline in cognitive function, memory, and daily activities. It is the most common cause of dementia in older adults and is characterized by the accumulation of abnormal protein deposits in the brain, including beta-amyloid plaques and tau tangles. The early symptoms of Alzheimer's disease include difficulty remembering recent events, disorientation, and problems with language and communication. As the disease progresses, individuals may experience personality changes, mood swings, difficulty with tasks such as bathing and dressing, and eventually, a loss of the ability to communicate and care for themselves. Some of the most commonly used medications include cholinesterase inhibitors, such as donepezil, galantamine, and rivastigmine, and N-methyl-D-aspartate (NMDA) receptor antagonists, such as memantine. It can also be treated by helping people maintain brain health, managing behavioral symptoms and slowing or delaying symptoms of the disease. 

Global Alzheimer’s Disease Market Trends:

One of the primary factors driving the market is the increasing aging population, who is more prone to neurodegenerative diseases like Alzheimer’s. Additionally, the growing number of individuals diagnosed with dementia and the rising awareness regarding Alzheimer’s disease has led to the adoption of newer treatments and medications for the disease. Apart from this, various medications are being approved by regulatory agencies to treat this disease. Other than this, the increasing penetration of smartphones and the internet, and the ease of ordering medications through an e-commerce platform also help in the early diagnosis and treatment of Alzheimer's disease. Furthermore, the constant developments of novel therapeutics that offer a strong safety and efficacy profile are creating lucrative growth opportunities for the key players operating in the industry. Moreover, extensive investments in the research and development (R&D) activities by key players to develop advanced technologies and several novel therapeutics that have a strong safety and efficacy profile are also expected to catalyze the growth of the market in the coming years. 

Market Summary:

• Region-wise, the market has been classified into United States, Germany, France, the United Kingdom, Italy, Spain, and Japan.
• This research study also offers a thorough overview of late-stage pipeline candidates and currently marketed medications for Alzheimer’s disease.
• The study also offers a thorough overview of the treatment practices for Alzheimer’s disease, the share of specific therapies, and the performance of key market players.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800